Denali Therapeutics Inc. (DNLI) stock
DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.00−0.08 (-0.44%)
Close on Nov 17, 2026Market cap $2.88BP/E –Yield –
Denali Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Denali Therapeutics's price to book ratio was 3.8× on Nov 11, 2026, against 3.1× a year earlier. Over the last 5 years it ranged from 1.6× to 5.4×, with a median of 3.0×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.8× | +1.2 |
| 2025 | Dec 31, 2025 | 2.6× | +0.4 |
| 2024 | Dec 31, 2024 | 2.2× | −0.4 |
| 2023 | Dec 29, 2023 | 2.6× | −1.6 |
| 2022 | Dec 30, 2022 | 4.2× | −1.1 |
| 2021 | Dec 31, 2021 | 5.4× | −6.0 |
| 2020 | Dec 31, 2020 | 11.4× | +7.6 |
| 2019 | Dec 31, 2019 | 3.8× | −0.4 |
| 2018 | Dec 31, 2018 | 4.2× | – |
See a number that looks wrong?